Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | FLT1 | P17948 | 2/20 | 0.54 |
| ▸ | FLT4 | P35916 | 2/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7219361 | 0.87 | LMNA (0.63) | LMNAPOLBTHRBRECQLTDP1 | |
| SCHEMBL4148502 | 0.83 | POLB (0.76) | LMNAPOLBTHRBRECQLTDP1 | |
| SCHEMBL381978 | 0.81 | KDM4E (0.68) | LMNAPOLBTHRBRECQLTDP1 | |
| SCHEMBL20359926 | 0.80 | FLT1 (0.61) | LMNAPOLBTHRBRECQLTDP1 | |
| SCHEMBL13181147 | 0.80 | LMNA (0.59) | LMNAPOLBTHRBRECQLTDP1 | |
| SCHEMBL7218397 | 0.79 | LMNA (0.67) | LMNAPOLBTHRBRECQLTDP1 | |
| SCHEMBL27496683 | 0.79 | LMNA (0.61) | LMNAPOLBTHRBRECQLTDP1 | |
| SCHEMBL13753905 | 0.78 | LMNA (0.65) | LMNAPOLBTHRBRECQLTDP1 | |
| Ammonia Solution, Strong SCHEMBL27375088 | 0.78 | LMNA (0.65) | LMNAPOLBTHRBRECQLTDP1 | |
| SCHEMBL13754012 | 0.78 | LMNA (0.78) | LMNAPOLBTHRBRECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356110-B1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-06 | — | — | EP | disclosed |
| EP-2356110-B1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-06 | — | — | EP | disclosed |
| US-8546565-B2 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546565-B2 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546565-B2 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| CN-102245596-A | Quinazolinamide derivatives | MERCK PATENT GMBH | 2011-11-16 | — | — | CN | disclosed |
| US-20110245225-A1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTING (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245225-A1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTING (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245225-A1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTING (DE) | 2011-10-06 | — | — | US | disclosed |
| EP-2356110-A1 | QUINAZOLINAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010066324-A1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010066324-A1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245225-A1 | QUINAZOLINAMIDE DERIVATIVES | HSP90AB1, HSP90AA1, HSP90B1 | LMNA 3355/4885POLB 3327/4885THRB 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.